Press Releases

Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
03/23/15Alkermes to Present Data on Aripiprazole Lauroxil and ALKS 3831 at 15th International Congress on Schizophrenia ResearchPrinter Friendly Version
03/09/15Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro Pharma, Inc.Printer Friendly Version
03/03/15Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare ConferencePrinter Friendly Version
03/02/15Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation, Depression and Other CNS DiseasesPrinter Friendly Version
02/24/15Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 35th Annual Health Care ConferencePrinter Friendly Version
02/24/15Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2014 and Provides Financial Expectations for 2015Printer Friendly Version
02/24/15Alkermes Announces Results From Phase 1 Study of ALKS 7106Printer Friendly Version
02/23/15Alkermes Announces Webcast of Analyst and Investor Event on March 2, 2015Printer Friendly Version
02/23/15Alkermes Appoints Mark Namchuk, Ph.D., As Senior Vice President of Research, Pharmaceutical and Nonclinical DevelopmentPrinter Friendly Version
02/17/15Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2014 Financial ResultsPrinter Friendly Version
02/09/15Alkermes Announces Positive Topline Results From Phase 1 Study of ALKS 8700 for Treatment of Multiple SclerosisPrinter Friendly Version
02/03/15Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
01/07/15Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in SchizophreniaPrinter Friendly Version
01/06/15Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/06/15Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive DisorderPrinter Friendly Version

Other Resources

Email Alerts

Stay in Touch with Alkermes